Kips Bay Medical — Investor Presentation (October 2013)
28 slides from Kips Bay Medical's investor presentation, Oct 21, 2013
Slide 1: Kips Bay Medical
KI AY MEDICALINCG “...advancing, refining, and improving cardiac surgery.”
Slide 2: Forward-Looking Statements Disclaimer
Forward-Looking Statements Disclaimer Certain statements in this presentation are forward-looking statements within the meaning of the Private Securities Litigation Reform Act of 1995 and are provided under the protection of the safe harbor for forward-looking statements provided by that Act. Forwar
Slide 3: Our Founder, Chairman and CEO
Our Founder, Chairman and CEO Manny Villafaña is our founder and the Chairman and CEO of Kips Bay Medical. Mr. Villafaña is globally recognized as a “Living Legend of Medicine”, an award-winning USA Master Entrepreneur, a member of the Minnesota Business and Science & Technology Halls of Fame and th
Slide 4: A Long History of Value Creation
$400 Million A Long History of Value Creation $27.2 B $15B+ Market Cap
Slide 5: What is CABG?
What is CABG? Coronary Artery Bypass Grafting involves the construction of an alternative path to bypass a narrowed or occluded coronary artery and restore blood flow from the aorta to an area past the occlusion. Coronary Artery Bypass Grafting (CABG)
Slide 6: Vein Grafts Don't Last as Long as Arterial Grafts
Internal Mammary Artery Saphenous Vein Synthetic Graft Implant Years 0 1 2 3 4 5 6 7 8 9 10 11 12 13 14 15 G r a f t P a t e n c y Coronary Artery Bypass Grafts Saphenous veins are larger in diameter and lack the thick muscular wall necessary to withstand the significantly higher pressure at the hea
Slide 7: What We Do
What We Do The innovative, new eSVS Mesh is designed to be fitted on the outside of a saphenous vein graft to strengthen the vein and to give that vein graft the physiological attributes of an artery by: Strengthening the vein graft to prevent vessel expansion and the resulting damage Reducing vein
Slide 8: Angiographic Results Control vs. Mesh
Angiographic Results Control vs. Mesh at 9 Months (Human) Untreated Venous Graft “Control” (1) Venous Graft Treated with eSVS Mesh (2) View Angiograms On-line
Slide 9: Angiographic Results Control vs. eSVS Mesh
Angiographic Results Control vs. eSVS Mesh at 9 Months (Human) Venous Graft Treated with eSVS Mesh (4) Untreated Venous Graft “Control” (3) View Angiograms On-line
Slide 10: Angiographic Results: Same Patient at 9 and 36 Months
36 months (6) 9 months (5) Angiographic Results Venous Graft Treated with eSVS Mesh Same Patient at 9 and 36 Months View Angiograms On-line
Slide 11: Angiographic Results: Same Patient at 9 and 36 Months
36 months (8) 9 months (7) Angiographic Results Venous Graft Treated with eSVS Mesh Same Patient at 9 and 36 Months View Angiograms On-line
Slide 12: CABG - Standard of Care for Multivessel Disease
CABG - Standard of Care for Multivessel Disease Study: Synergy Between Percutaneous Coronary Intervention with Taxus and Cardiac Surgery (the “SYNTAX” study) Originally published in the New England Journal of Medicine March 2009. Five-year follow up data published in The Lancet February 2013. Evalua
Slide 13: Annual World-Wide Market: 2.0 Million Potential Grafts
CABG Procedures: 800,000 annually with 3.5 Grafts per Procedure of which 2.5 Grafts per Procedure are Saphenous 2.0 Million Potential eSVS MESH Grafts Annually Wholesale ASP @ $1,200 per unit Retail ASP @ $2,500 per unit 70%+ margin potential Annual World-Wide Market =
Slide 14: Clinical Progress of the eSVS Mesh
“eMESH I” Feasibility Trial for U.S. FDA – in progress International Feasibility Trial – CE Mark Approval – May 2010 Supported CE Mark approval Created significant questions for the FDA Follow-up Angio’s from first International Trail Dubai, UAE – single center experience (complete) Switzerland – si
Slide 15: eMESH I Clinical Feasibility Trial
“eMESH I” Clinical Feasibility Trial A study designed to demonstrate to the U.S. FDA the initial safety and performance of the eSVS Mesh: Prospective, randomized study of up to 120 patients. Currently targeting 10 investigational sites in Europe and 4* in the U.S. Primary performance endpoint is the
Slide 16: OUS and US Trial Sites
OUS Sites University Hospital Bern, Switzerland - Dr. Lars Englberger (International PI) Bordeaux University Hospital, Pessac, France - Prof. Louis Labrousse C.H.U. Dupuytren, Limoges, France - Dr. Marc Laskar G. Pasquinucci Heart Hospital, Massa, Italy - Dr. Mattia Glauber University Hospital Nante
Slide 17: Dubai, UAE Retrospective Study
Dr. Uwe Klima, Professor, MD - American Hospital Dubai. Retrospective implant study with prospective follow-up of commercially implanted eSVS Mesh. All eligible SVGs treated with eSVS Mesh. Patients underwent follow-up CT angiography an average of 6 months (3-14 months) post implant. 30 eSVS Mesh de
Slide 18: eSVS Mesh Holds Vein Graft Open
The eSVS Mesh holds this vein graft open for easier suturing and the graft does not kink as it drapes over the side of the surgical towel.
Slide 19: eSVS Mesh Supported Vein Graft CT Scan
eSVS Mesh Supported Vein Graft 6 Months CT Scan (Human) The eSVS Mesh is compatible with CT Imaging
Slide 20: IVUS Interpretation
IVUS Interpretation eSVS and Control Vein Segments 14 months Post Implant (Single Frame at Mid Graft) Control Vein LCX eSVS Mesh Vein RCA Intravascular ultrasound reveals the wall thickening in the “Control” graft
Slide 21: Upcoming Milestones
Upcoming Milestones Qi ary [Feasibility Study Enrollment Follow Up Pivotal Study | ————— Protocol Review with FDA Furope Envollment (Early Start) ———s IDE Approval for US Engollment US Enrollment — MEDICALING
Slide 22: International Marketing Strategy
Independent distributor model We require distributor to have an established client base in cardiac surgery Currently have 13 distributors covering 45 countries All contracts in US dollars Mr. Villafaña has established commercially successful independent distributor networks in past companies: Cardia
Slide 23: Solid Intellectual Property Position
Our issued patents and pending patent applications include claims directed towards: resilient and compliant structure. providing structural support which inhibits vessel expansion. providing a graft with physiological attributes similar to those of an artery. methods critical to the surgical procedu
Slide 24: Platform for the Future
Knitted Nitinol Technology CABG Surgery Dialysis Access Grafts Synthetic Grafts for CABG Peripheral Bypass Surgery Platform for the Future
Slide 25: Capitalization - June 29, 2013
Capitalization - June 29, 2013 Debt - - % Common Stock $0.01 par value common shares (40M authorized) 26,979,079 85.66% Undesignated preferred shares (10M authorized) - - % Option Pool: Option shares granted & outstanding - '07 Plan 1,473,750 4.68% Option shares granted & outstanding - '13 Plan 0 0.
Slide 26: Investment Highlights
New medical technology in a company founded by Manny Villafaña. CE Mark approval & 500+ implants to date - early indication of device success. Experienced management team with history of success. eSVS MESH technology to address limitations in CABG surgery with world-wide potential for 2.0 million eS
Slide 27: Thank You!
KiPSeBay MEDICALINCG “,, advancing, refining, and improving cardiac surgery.” Thank You!
Slide 28: Descriptions of the angiogram videos included in this presentation
Descriptions of the angiogram videos included in this presentation The foregoing presentation includes a series of embedded coronary angiogram videos. An angiogram is an X-ray test that uses a special dye and camera (fluoroscopy) to take pictures of the blood flow in an artery or a vein. During a co
Kips Bay Medical — Investor Presentation (October 2013) on 6ix